A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
- PMID: 20496177
- PMCID: PMC3338170
- DOI: 10.1007/s00520-010-0911-0
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a troublesome chronic symptom that has no proven pharmacologic treatment. The purpose of this double-blind randomized placebo-controlled trial was to evaluate a novel compounded topical gel for this problem.
Methods: Patients with CIPN were randomized to baclofen 10 mg, amitriptyline HCL 40 mg, and ketamine 20 mg in a pluronic lecithin organogel (BAK-PLO) versus placebo (PLO) to determine its effect on numbness, tingling, pain, and function. The primary endpoint was the baseline-adjusted sensory subscale of the EORTC QLQ-CIPN20, at 4 weeks.
Results: Data in 208 patients reveal a trend for improvement that is greater in the BAK-PLO arm over placebo in both the sensory (p = 0.053) and motor subscales (p = 0.021). The greatest improvements were related to the symptoms of tingling, cramping, and shooting/burning pain in the hands as well as difficulty in holding a pen. There were no undesirable toxicities associated with the BAK-PLO and no evidence of systemic toxicity.
Conclusion: Topical treatment with BAK-PLO appears to somewhat improve symptoms of CIPN. This topical gel was well tolerated, without evident systemic toxicity. Further research is needed with increased doses to better clarify the clinical role of this treatment in CIPN.
Figures
Similar articles
-
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.Support Care Cancer. 2014 Jul;22(7):1807-14. doi: 10.1007/s00520-014-2158-7. Epub 2014 Feb 16. Support Care Cancer. 2014. PMID: 24531792 Free PMC article. Clinical Trial.
-
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.Support Care Cancer. 2012 Mar;20(3):625-32. doi: 10.1007/s00520-011-1141-9. Epub 2011 Apr 12. Support Care Cancer. 2012. PMID: 21479990 Free PMC article. Clinical Trial.
-
High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies.Support Care Cancer. 2019 Aug;27(8):3053-3059. doi: 10.1007/s00520-018-4618-y. Epub 2019 Jan 4. Support Care Cancer. 2019. PMID: 30607681 Clinical Trial.
-
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2014 Jun 20;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. Epub 2014 Apr 14. J Clin Oncol. 2014. PMID: 24733808 Review.
-
Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.Acta Oncol. 2015 May;54(5):587-91. doi: 10.3109/0284186X.2014.995775. Epub 2015 Mar 9. Acta Oncol. 2015. PMID: 25751757 Review.
Cited by
-
Platinum-induced neurotoxicity and preventive strategies: past, present, and future.Oncologist. 2015 Apr;20(4):411-32. doi: 10.1634/theoncologist.2014-0044. Epub 2015 Mar 12. Oncologist. 2015. PMID: 25765877 Free PMC article. Review.
-
The Efficacy of Ketamine for Acute and Chronic Pain in Patients with Cancer: A Systematic Review of Randomized Controlled Trials.Healthcare (Basel). 2024 Aug 6;12(16):1560. doi: 10.3390/healthcare12161560. Healthcare (Basel). 2024. PMID: 39201120 Free PMC article. Review.
-
The Ameliorative Effect of Thymoquinone on Vincristine-Induced Peripheral Neuropathy in Mice by Modulating Cellular Oxidative Stress and Cytokine.Life (Basel). 2022 Dec 29;13(1):101. doi: 10.3390/life13010101. Life (Basel). 2022. PMID: 36676049 Free PMC article.
-
Cancer treatment-related neuropathic pain syndromes--epidemiology and treatment: an update.Curr Pain Headache Rep. 2014 Nov;18(11):459. doi: 10.1007/s11916-014-0459-7. Curr Pain Headache Rep. 2014. PMID: 25239766 Review.
-
New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Asia Pac J Oncol Nurs. 2016 Jan-Mar;3(1):73-85. doi: 10.4103/2347-5625.170977. Asia Pac J Oncol Nurs. 2016. PMID: 27981142 Free PMC article.
References
-
- Cavaletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin. Cancer. 1995;75:1141–1150. - PubMed
-
- Cavaletti G, Fabbrica D, Minoia C, et al. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9:443–447. - PubMed
-
- Ocean JA, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004;12:619–625. - PubMed
-
- Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical andneurophysiological study of 23 patients. Ital JNeurol Sci. 1997;18:73–79. - PubMed
-
- Rowinsky EK, Chaudry V, Cornblath DR, et al. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;15:107–115. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA035267/CA/NCI NIH HHS/United States
- CA124477/CA/NCI NIH HHS/United States
- CA-37404/CA/NCI NIH HHS/United States
- K05 CA124477/CA/NCI NIH HHS/United States
- CA-35195/CA/NCI NIH HHS/United States
- U10 CA037404/CA/NCI NIH HHS/United States
- CA-25224/CA/NCI NIH HHS/United States
- CA-35113/CA/NCI NIH HHS/United States
- U10 CA035113/CA/NCI NIH HHS/United States
- CA-35415/CA/NCI NIH HHS/United States
- U10 CA035431/CA/NCI NIH HHS/United States
- CA-37417/CA/NCI NIH HHS/United States
- CA-35448/CA/NCI NIH HHS/United States
- U10 CA025224/CA/NCI NIH HHS/United States
- U10 CA035103/CA/NCI NIH HHS/United States
- U10 CA037417/CA/NCI NIH HHS/United States
- N01 CA035431/CA/NCI NIH HHS/United States
- R21 CA131795/CA/NCI NIH HHS/United States
- U10 CA035448/CA/NCI NIH HHS/United States
- U10 CA063848/CA/NCI NIH HHS/United States
- U10 CA035195/CA/NCI NIH HHS/United States
- CA-35103/CA/NCI NIH HHS/United States
- CA-63848/CA/NCI NIH HHS/United States
- U10 CA035415/CA/NCI NIH HHS/United States
- U10 CA063849/CA/NCI NIH HHS/United States
- CA-35267/CA/NCI NIH HHS/United States
- CA-63849/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical